Biocon Biologics sees insulin demand growing across markets, says CEO Tambe
Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...
TCTMD1h
Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations
The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.
Healio7h
Cardiometabolic drugs consume majority of cost among those up for price negotiation
Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...
Daijiworld18h
Celltrion gets US FDA approval for new biosimilar for autoimmune disease treatment
Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug Administration (FDA). The ...
cnbctv1815h
Biocon Biologics CEO expects core margin improvement, outlines upcoming launches
Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.
centerforbiosimilars12h
The Top 5 Biosimilar Articles for the Week of January 27
Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...
centerforbiosimilars9h
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
PipelineReview.com16h
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...